

09553386

ted fatty acid ester
81735 CONJUGATED
310982 FATTY
3501411 ACID
467420 ESTER
L23 6 CONJUGATED FATTY ACID ESTER
(CONJUGATED (W) FATTY (W) ACID (W) ESTER)

=> d 123 1-6 ibib hitstr abs

L23 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:864408 CAPLUS
DOCUMENT NUMBER: 137:354693
TITLE: Catalytic isomerization process for conjugating fatty
acid esters
INVENTOR(S): Abney, Curt; Anderson, John
PATENT ASSIGNEE(S): AG Processing Inc., USA
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6479683	B1	20021112	US 2001-800034	20010306

PRIORITY APPLN. INFO.: US 2001-800034 20010306
AB A process for producing conjugated fatty acid esters comprises: (a) providing a substrate contg. at least one unconjugated polyene fatty acid ester; (b) forming a reaction mixt. by combining the substrate with 1-5% of an alkali metal alkoxide catalyst and 1-5% of a monohydric alc. solvent, wherein the ratio of catalyst to solvent is from about 1:0.5 to about 1:3; and (c) subjecting the reaction mixt. to a base-catalyzed isomerization reaction in a closed vessel at a temp. of 275-350 .degree.F and under the corresponding autogenic pressure for a time sufficient to generate a reaction product contg. conjugated fatty acid Me esters and potassium salts of conjugated fatty acids, in which at least about 90% of the unconjugated polyene fatty acid esters have been converted into conjugated forms.

REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:430012 CAPLUS
DOCUMENT NUMBER: 135:182305
TITLE: Preparation of conjugated soybean oil and other natural oils and fatty acids by homogeneous transition metal catalysis
AUTHOR(S): Larock, Richard C.; Dong, Xiaoyang; Chung, Steven; Reddy, Ch. Kishan; Ehlers, Laurie E.
CORPORATE SOURCE: Department of Chemistry, Iowa State University, Ames, IA, 50011, USA
SOURCE: Journal of the American Oil Chemists' Society (2001), 78(5), 447-453
CODEN: JAOCA7; ISSN: 0003-021X
PUBLISHER: AOCS Press
DOCUMENT TYPE: Journal
LANGUAGE: English

1/7/2003

09553386

AB The use of as little as 0.1 mol% $[\text{RhCl}(\text{C}_8\text{H}_{14})_2]_2$, 0.25 mol% $\text{PtCl}_2(\text{PPh}_3)_2$, or 0.5 mol% $\text{RuHCl}(\text{CO})(\text{PPh}_3)_3$, where Ph = Ph, catalyzes the isomerization of soybean oil to conjugated soybean oil under mild reaction conditions and in high yields. No hydrogenation products are detected with any of these catalysts. Preliminary phys. tests have shown that the conjugated soybean oil has exceptional drying properties and the resulting coatings exhibit good solvent resistance. The $[\text{RhCl}(\text{C}_8\text{H}_{14})_2]_2$ catalyst provides similarly high yields of other conjugated vegetable oils, conjugated linoleic acid, and conjugated Et linoleate. Other rhodium catalysts, such as $\text{RhCl}(\text{PPh}_3)_3$, have also been found to be effective for the conjugation of Et linoleate.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:214011 CAPLUS

DOCUMENT NUMBER: 116:214011

TITLE: Preparation of ethenyl-branched polyunsaturated C20-24-fatty acids or their esters by ethenylation of polyunsaturated fatty acids

INVENTOR(S): Laufenberg, Alfred; Behr, Arno

PATENT ASSIGNEE(S): Henkel K.-G.a.A., Germany

SOURCE: Ger. Offen., 6 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4002012	A1	19910725	DE 1990-4002012	19900124
WO 9111428	A1	19910808	WO 1991-EP54	19910115
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
EP 511986	A1	19921111	EP 1991-902198	19910115
EP 511986	B1	19941214		
R: DE, FR, GB, IT				
JP 05507264	T2	19931021	JP 1991-502440	19910115
US 5324847	A	19940628	US 1992-915696	19920724
PRIORITY APPLN. INFO.:			DE 1990-4002012	19900124
			WO 1991-EP54	19910115

AB The prepn. of olefinic adducts of ethylene with polyunsatd. C18-22-fatty acids or C18-22-fatty C1-36-alkyl esters comprises the treatment of said fatty acids or their esters with ethylene in a 1:1-1:3-molar ratio at elevated temp. and pressure in the presence of a Ru, Ir, Pd, or Pt catalyst. A mixt. of 8.2 g fatty acid mixt. contg. 56% by wt. 18:2 conjugated fatty acids, 100 mg $\text{RhCl}_3 \cdot 3\text{H}_2\text{O}$, 10 mL hexane, and ethylene (30 bar) was heated to 100.degree. in an autoclave for 20 h to give in 63.1% yield a mixt. contg. 34.9% 1:1 ethylene-conjugated fatty acid ester adduct, 44.2% 2:1 adduct, and 20.9% 3:1 adduct.

L23 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1991:582647 CAPLUS

DOCUMENT NUMBER: 115:182647

TITLE: Preapration of propenyl-branched polyunsaturated C21-25-fatty acids or their esters by propenylation of polyunsaturated fatty acids

1/7/2003

09553386

INVENTOR(S): Laufenberg, Alfred; Behr, Arno
PATENT ASSIGNEE(S): Henkel K.-G.a.A., Germany
SOURCE: Ger. Offen., 5 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4002008	A1	19910725	DE 1990-4002008	19900124
WO 9111427	A1	19910808	WO 1991-EP52	19910115
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
JP 05503928	T2	19930624	JP 1991-502537	19910115
EP 594580	A1	19940504	EP 1991-902688	19910115
EP 594580	B1	19960320		
R: DE, FR, GB, IT				
US 5420317	A	19950530	US 1992-915844	19920724

PRIORITY APPLN. INFO.: DE 1990-4002008 19900124
WO 1991-EP52 19910115

AB The prepn. of olefinic adducts of propylene with polyunsatd. C18-22-fatty acids or C18-22-fatty C1-36-alkyl esters comprises the treatment of said fatty acids or their esters with propylene in a 1:1-1:2-molar ratio at elevated temp. and pressure in the presence of a Ru, Ir, Pd, or Pt catalyst. A mixt. of 301 g fatty acid mixt. contg. 60.3% by wt. 18:2 conjugated fatty acid Me esters, 6.2% by wt. Me linoleate, and 24.4% by wt. Me oleate, 881.6 mg RhCl₃.3H₂O, 350 mL hexane, and 100 g propene was heated to 100.degree. in an autoclave for 20 h to give in 91.9% yield a mixt. contg. 85.2% 1:1 and 6.5% 2:1 propene-conjugated fatty acid ester adduct.

L23 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1973:468073 CAPLUS
DOCUMENT NUMBER: 79:68073
TITLE: Fatty acid esters with conjugated double bonds
INVENTOR(S): Ritz, Juergen; Reese, Johannes
PATENT ASSIGNEE(S): Reichhold-Albert-Chemie A.-G.
SOURCE: Ger. Offen., 9 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2155727	A1	19730517	DE 1971-2155727	19711110
DE 2155727	C3	19820616		
ES 408287	A1	19751116	ES 1972-408287	19721104
CA 1010057	A1	19770510	CA 1972-155797	19721107
FR 2159401	A1	19730622	FR 1972-39678	19721109
FR 2159401	B1	19771230		
BR 7207874	A0	19730823	BR 1972-7874	19721109
IT 970355	A	19740410	IT 1972-31479	19721109
JP 49067909	A2	19740702	JP 1972-111689	19721109
AT 324288	B	19750825	AT 1972-9535	19721109
CH 578044	A	19760730	CH 1972-16293	19721109

1/7/2003

09553386

NL 7215287	A	19730514	NL 1972-15287	19721110
NL 173658	B	19830916		
NL 173658	C	19840216		
GB 1408189	A	19751001	GB 1972-52090	19721110
US 3984444	A	19761005	US 1974-529377	19741204

PRIORITY APPLN. INFO.:
DE 1971-2155727 19711110
DE 1972-2250232 19721013
US 1972-304927 19721109

AB Soybean fatty acid Me ester, soybean oil, linseed oil, and sunflower oil were isomerized by treatment with MeOK or Me3COK in dimethyl sulfoxide [67-68-5], DMF [68-12-2], hexamethylphosphoric triamide [680-31-9], or N-methylpyrrolidone [872-50-4] to give products of conjugated double bonds. Thus, soybean oil was treated with MeOK in DMF under N for 24 hr at 20.deg. to give 100% oil with degree of conjugation 98%.

L23 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1964:46135 CAPLUS
DOCUMENT NUMBER: 60:46135
ORIGINAL REFERENCE NO.: 60:8158a-c
TITLE: Fatty acid ester copolymers with vinylaromatic compounds
PATENT ASSIGNEE(S): Harburger Fettchemie Brinckman & Mergell G.m.b.H.
SOURCE: 20 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 627128		19630430	BE	
DE 1228247			DE	
GB 988737			GB	
US 3271432		1966	US	

PRIORITY APPLN. INFO.: DE 19620425

AB Esters of unsatd., conjugated fatty acids are copolymerized with a vinyl aromatic compd., such as styrene (styrene/fatty acid mole ratio 0.5:1-2.1), in the presence of a strong mineral acid or a Friedel-Crafts catalyst and butylpyrocatechol (I) to give the title compds. which can be used in the prepn. of resins, elastomers, and coatings. Thus, a mixt. of 360 kg. Me ester of isomerized soybean oil fatty acid, 18.7 kg. styrene stabilized with 0.1% I, and 1% (of reactants) bleaching clay activated with HCl, styrene:conjugated acid mole ratio 0.1, is heated at 70-150.degree. until a const. viscosity is obtained, heated for 1 hr. at 180.degree., cooled to .apprx.80.degree., and distd. at 0.6 mm. after 4-6 hrs. reaction time to give 42.7% -distillate, sapon. no. 186, equiv. wt. 301, and 57.3% residue, sapon. no. 174.4, equiv. wt. 321.

=>

09553386

11/14/97

Priority

Welcome to STN International! Enter x:x

LOGINID:sssptal202sxq

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 32 Nov 18 DKILIT has been renamed APOLLIT
NEWS 33 Nov 25 More calculated properties added to REGISTRY
NEWS 34 Dec 02 TIBKAT will be removed from STN
NEWS 35 Dec 04 CSA files on STN
NEWS 36 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 37 Dec 17 TOXCENTER enhanced with additional content
NEWS 38 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 39 Dec 30 ISMEC no longer available

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability

1/7/2003

09553386

NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:53:46 ON 07 JAN 2003

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:53:54 ON 07 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jan 2003 VOL 138 ISS 2
FILE LAST UPDATED: 6 Jan 2003 (20030106/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s phytostenol ester
2 PHYTOSTENOL
467420 ESTER
L1 0 PHYTOSTENOL ESTER
(PHYTOSTENOL(W) ESTER)

=> stenol ester
STENOL IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.

1/7/2003

09553386

For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s stenol ester
110 STENOL
467420 ESTER
L2 0 STENOL ESTER
(STENOL(W)ESTER)

=> s fatty acid
310982 FATTY
3501411 ACID
L3 172592 FATTY ACID
(FATTY(W)ACID)

=> s l3 and conjugated
81735 CONJUGATED
L4 2073 L3 AND CONJUGATED

=> s l4 and esters
356293 ESTERS
L5 497 L4 AND ESTERS

=> s l5 and stenol
110 STENOL
L6 0 L5 AND STENOL

=> s l5 and atanol
0 ATANOL
L7 0 L5 AND ATANOL

=> s l5 and stanol
242 STANOL
L8 2 L5 AND STANOL

=> s l5 and phytosterols
1449 PHYTOSTEROLS
L9 1 L5 AND PHYTOSTEROLS

=> d l8 1-2 ibib hitstr abs

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:338762 CAPLUS
DOCUMENT NUMBER: 134:362292
TITLE: Methods of determining individual hypersensitivity to
a pharmaceutical agent from gene expression profile
INVENTOR(S): Farr, Spencer
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

1/7/2003

09553386

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to det. the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predetd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:300735 CAPLUS

DOCUMENT NUMBER: 134:311353

TITLE: Process for their production of sterol **esters**
of **conjugated** linoleic acid for lowering
serum cholesterol levels

INVENTOR(S): Liu, Linsen

PATENT ASSIGNEE(S): The Board of Regents for Oklahoma State University,
USA

SOURCE: PCT Int. Appl., 14 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001029060	A2	20010426	WO 2000-US41373	20001020
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

1/7/2003

09553386

AU 2001021187 A5 20010430 AU 2001-21187 20001020
US 6413571 B1 20020702 US 2000-693562 20001020
PRIORITY APPLN. INFO.: US 1999-160894P P 19991021
WO 2000-US41373 W 20001020

OTHER SOURCE(S): CASREACT 134:311353

AB The invention discloses a process for the prepn. of sterol/**stanol esters of conjugated fatty acid** through the esterification or transesterification of sterol or hydrogenated form thereof (**stanol**). Such novel **esters** exhibit the combined properties normally possessed by the sterol/**stanol** compd. and the **conjugated fatty acid** and as such are excellent additives for dietetic foods and supplements.

=> d 19 ibib hitstr abs

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1987:493262 CAPLUS

DOCUMENT NUMBER: 107:93262

TITLE: Growth support and metabolism of **phytosterols** in Paramecium tetraurelia

AUTHOR(S): Whitaker, Bruce D.; Nelson, David L.

CORPORATE SOURCE: Coll. Agric. Life Sci., Univ. Wisconsin, Madison, WI, 53706, USA

SOURCE: Lipids (1987), 22(6), 386-96

CODEN: LPDSAP; ISSN: 0024-4201

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Under certain conditions, sterols that fail to support growth (e.g., cholesterol) can be esterified in large amts. of Paramecium. There was no compelling evidence to support the hypothesis that steryl **esters** serve a specialized role in the **fatty acid** metab. of the cell. Octadecenoic acid, essential for cell growth, was the major **fatty acid** in both steryl **esters** and triglycerides. P. tetraurelia Dehydrogenated .DELTA.0 and .DELTA.7, as well as .DELTA.5-3.beta.-hydroxy sterols, to yield the **conjugated** 5,7-diene deriv. These results indicate the presence of a .DELTA.5, in addn. to a .DELTA.7, desaturase of the sterol nucleus in this ciliate. Two C24 .alpha.-Et sterols, .DELTA.22-stigmastenol (.DELTA.22) and stigmastanol (.DELTA.0), were shown for the first time to promote growth. Finally, it was found that non-growth-promoting sterols may compose a high percentage of the free sterols of the surface membrane without adversely affecting cell growth or viability. These data support the conclusion that the growth requirement for select **phytosterols** in Paramecium does not involve the structural or functional role of bulk sterols in cell membranes.

09553386

Welcome to STN International! Enter x:x

LOGINID:sssptal202sxq

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 32 Nov 18 DKILIT has been renamed APOLLIT
NEWS 33 Nov 25 More calculated properties added to REGISTRY
NEWS 34 Dec 02 TIBKAT will be removed from STN
NEWS 35 Dec 04 CSA files on STN
NEWS 36 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 37 Dec 17 TOXCENTER enhanced with additional content
NEWS 38 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 39 Dec 30 ISMEC no longer available

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability

1/7/2003

09553386

NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:53:46 ON 07 JAN 2003

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:53:54 ON 07 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jan 2003 VOL 138 ISS 2

FILE LAST UPDATED: 6 Jan 2003 (20030106/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s phytostenol ester

2 PHYTOSTENOL

467420 ESTER

L1 0 PHYTOSTENOL ESTER

(PHYTOSTENOL(W) ESTER)

=> stenol ester

STENOL IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

1/7/2003

09553386

For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

```
=> s stenol ester
      110 STENOL
      467420 ESTER
L2      0 STENOL ESTER
        (STENOL(W) ESTER)
```

```
=> s fatty acid
      310982 FATTY
      3501411 ACID
L3      172592 FATTY ACID
        (FATTY(W) ACID)
```

```
=> s l3 and conjugated
      81735 CONJUGATED
L4      2073 L3 AND CONJUGATED
```

```
=> s l4 and esters
      356293 ESTERS
L5      497 L4 AND ESTERS
```

```
=> s l5 and stenol
      110 STENOL
L6      0 L5 AND STENOL
```

```
=> s l5 and atanol
      0 ATANOL
L7      0 L5 AND ATANOL
```

```
=> s l5 and stanol
      242 STANOL
L8      2 L5 AND STANOL
```

```
=> s l5 and phytosterols
      1449 PHYTOSTEROLS
L9      1 L5 AND PHYTOSTEROLS
```

```
=> d l8 1-2 ibib hitstr abs
```

```
L8  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:      2001:338762  CAPLUS
DOCUMENT NUMBER:      134:362292
TITLE:                Methods of determining individual hypersensitivity to
                        a pharmaceutical agent from gene expression profile
INVENTOR(S):          Farr, Spencer
PATENT ASSIGNEE(S):   Phase-1 Molecular Toxicology, USA
SOURCE:               PCT Int. Appl., 222 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:        Patent
LANGUAGE:             English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

1/7/2003

09553386

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to det. the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predetd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:300735 CAPLUS

DOCUMENT NUMBER: 134:311353

TITLE: Process for their production of sterol **esters**
of **conjugated** linoleic acid for lowering
serum cholesterol levels

INVENTOR(S): Liu, Linsen

PATENT ASSIGNEE(S): The Board of Regents for Oklahoma State University,
USA

SOURCE: PCT Int. Appl., 14 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001029060	A2	20010426	WO 2000-US41373	20001020
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

1/7/2003

09553386

AU 2001021187 A5 20010430 AU 2001-21187 20001020
US 6413571 B1 20020702 US 2000-693562 20001020
PRIORITY APPLN. INFO.: US 1999-160894P P 19991021
WO 2000-US41373 W 20001020

OTHER SOURCE(S): CASREACT 134:311353

AB The invention discloses a process for the prepn. of sterol/**stanol esters of conjugated fatty acid** through the esterification or transesterification of sterol or hydrogenated form thereof (**stanol**). Such novel **esters** exhibit the combined properties normally possessed by the sterol/**stanol** compd. and the **conjugated fatty acid** and as such are excellent additives for dietetic foods and supplements.

=> d l9 ibib hitstr abs

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1987:493262 CAPLUS

DOCUMENT NUMBER: 107:93262

TITLE: Growth support and metabolism of **phytosterols** in Paramecium tetraurelia

AUTHOR(S): Whitaker, Bruce D.; Nelson, David L.

CORPORATE SOURCE: Coll. Agric. Life Sci., Univ. Wisconsin, Madison, WI, 53706, USA

SOURCE: Lipids (1987), 22(6), 386-96

CODEN: LPDSAP; ISSN: 0024-4201

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Under certain conditions, sterols that fail to support growth (e.g., cholesterol) can be esterified in large amts. of Paramecium. There was no compelling evidence to support the hypothesis that steryl **esters** serve a specialized role in the **fatty acid** metab. of the cell. Octadecenoic acid, essential for cell growth, was the major **fatty acid** in both steryl **esters** and triglycerides. P. tetraurelia Dehydrogenated .DELTA.0 and .DELTA.7, as well as .DELTA.5-3.beta.-hydroxy sterols, to yield the **conjugated** 5,7-diene deriv. These results indicate the presence of a .DELTA.5, in addn. to a .DELTA.7, desaturase of the sterol nucleus in this ciliate. Two C24 .alpha.-Et sterols, .DELTA.22-stigmastenol (.DELTA.22) and stigmastanol (.DELTA.0), were shown for the first time to promote growth. Finally, it was found that non-growth-promoting sterols may compose a high percentage of the free sterols of the surface membrane without adversely affecting cell growth or viability. These data support the conclusion that the growth requirement for select **phytosterols** in Paramecium does not involve the structural or functional role of bulk sterols in cell membranes.

=> d his

(FILE 'HOME' ENTERED AT 11:53:46 ON 07 JAN 2003)

FILE 'CAPLUS' ENTERED AT 11:53:54 ON 07 JAN 2003

L1 0 S PHYTOSTENOL ESTER
L2 0 S STENOL ESTER
L3 172592 S FATTY ACID
L4 2073 S L3 AND CONJUGATED
L5 497 S L4 AND ESTERS

1/7/2003

09553386

L6 0 S L5 AND STENOL
L7 0 S L5 AND ATANOL
L8 2 S L5 AND STANOL
L9 1 S L5 AND PHYTOSTEROLS

=> s l5 and cholesterol

135044 CHOLESTEROL
L10 51 L5 AND CHOLESTEROL

=> s l10 and stanols

310 STANOLS
L11 0 L10 AND STANOLS

=> s l10 and phytosterols

1449 PHYTOSTEROLS
L12 1 L10 AND PHYTOSTEROLS

=> s l10 and sterols

19162 STEROLS
L13 9 L10 AND STEROLS

=> s l10 and phytostenols

1 PHYTOSTENOLS
L14 1 L10 AND PHYTOSTENOLS

=> s l10 and stenols

55 STENOLS
L15 0 L10 AND STENOLS

=> d l14 ibib hitstr abs

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:344854 CAPLUS

DOCUMENT NUMBER: 130:347399

TITLE: Use of mixtures containing **phytostenols** for
producing hypocholesteremic preparations

INVENTOR(S): Fabry, Bernd

PATENT ASSIGNEE(S): Henkel Kommanditgesellschaft auf Aktien, Germany

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9925362	A1	19990527	WO 1998-EP7059	19981105
W: AU, BG, BR, BY, CA, CN, CZ, HU, ID, IS, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SI, SK, TR, UA, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19750453	A1	19990527	DE 1997-19750453	19971114
CA 2310026	AA	19990527	CA 1998-2310026	19981105
AU 9915603	A1	19990607	AU 1999-15603	19981105
AU 737638	B2	20010823		
EP 1028733	A1	20000823	EP 1998-959848	19981105
R: DE, ES, FR, GB, IT, NL				
JP 2001523641	T2	20011127	JP 2000-520795	19981105

1/7/2003

09553386

PRIORITY APPLN. INFO.:

DE 1997-19750453 A 19971114

WO 1998-EP7059 W 19981105

OTHER SOURCE(S): MARPAT 130:347399

AB Mixts. of active agents contg. (a) **phytostenols** and/or phytostenol **esters** and (b) **conjugated** fatty acids or their glycerides are used to produce hypocholesteremic preps. These mixts. have a synergistic effect in reducing the **cholesterol** content of serum. When encapsulated in gelatin, the preps. can be administered orally in high doses without any problems; they may also be incorporated into food products. Thus, the contents of a 1.5-g capsule, contg. 5 wt.% .beta.-sitostanyl laurate, 5 wt.% **conjugated** linoleic acid, and radiolabeled **cholesterol**, were administered to fasting rats by gavage. The radioactivity level in the blood 48 h later was 12% of that in rats fed labeled **cholesterol** alone, and was also markedly lower than that in rats given either the phytostanol or the **fatty acid** alone.

REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l12 ibib hitste abs

'HITSTE' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)

1/7/2003

containing hit terms

HITRN ----- HIT RN and its text modification

HITSTR ----- HIT RN, its text modification, its CA index name, and its structure diagram

HITSEQ ----- HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields

FHITSTR ----- First HIT RN, its text modification, its CA index name, and its structure diagram

FHITSEQ ----- First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields

KWIC ----- Hit term plus 20 words on either side

OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):end

=> d l12 ibib hitstr abs

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1987:493262 CAPLUS

DOCUMENT NUMBER: 107:93262

TITLE: Growth support and metabolism of **phytosterols** in *Paramecium tetraurelia*

AUTHOR(S): Whitaker, Bruce D.; Nelson, David L.

CORPORATE SOURCE: Coll. Agric. Life Sci., Univ. Wisconsin, Madison, WI, 53706, USA

SOURCE: Lipids (1987), 22(6), 386-96

CODEN: LPDSAP; ISSN: 0024-4201

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Under certain conditions, sterols that fail to support growth (e.g., **cholesterol**) can be esterified in large amts. of *Paramecium*. There was no compelling evidence to support the hypothesis that steryl **esters** serve a specialized role in the **fatty acid** metab. of the cell. Octadecenoic acid, essential for cell growth, was the major **fatty acid** in both steryl **esters** and triglycerides. *P. tetraurelia* Dehydrogenated .DELTA.0 and .DELTA.7, as well as .DELTA.5-3.beta.-hydroxy sterols, to yield the **conjugated** 5,7-diene deriv. These results indicate the presence of a .DELTA.5, in addn. to a .DELTA.7, desaturase of the sterol nucleus in this ciliate. Two C24 .alpha.-Et sterols, .DELTA.22-stigmastenol (.DELTA.22) and stigmastanol (.DELTA.0), were shown for the first time to promote growth. Finally, it was found that non-growth-promoting sterols may compose a high percentage of the free sterols of the surface membrane without adversely affecting cell growth or viability. These data support the conclusion that the growth requirement for select **phytosterols** in *Paramecium* does not involve the structural or functional role of bulk sterols in cell membranes.

09553386

=> d l13 1-9 ibib hitstr abs

L13 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:338762 CAPLUS
DOCUMENT NUMBER: 134:362292
TITLE: Methods of determining individual hypersensitivity to
a pharmaceutical agent from gene expression profile
INVENTOR(S): Farr, Spencer
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to det. the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predetd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.

L13 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:300735 CAPLUS
DOCUMENT NUMBER: 134:311353
TITLE: Process for their production of sterol **esters**
of **conjugated** linoleic acid for lowering
serum **cholesterol** levels
INVENTOR(S): Liu, Linsen
PATENT ASSIGNEE(S): The Board of Regents for Oklahoma State University,

1/7/2003

09553386

SOURCE: USA
PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001029060	A2	20010426	WO 2000-US41373	20001020
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001021187	A5	20010430	AU 2001-21187	20001020
US 6413571	B1	20020702	US 2000-693562	20001020
PRIORITY APPLN. INFO.:			US 1999-160894P P	19991021
			WO 2000-US41373 W	20001020

OTHER SOURCE(S): CASREACT 134:311353

AB The invention discloses a process for the prepn. of sterol/sterol **esters of conjugated fatty acid** through the esterification or transesterification of sterol or hydrogenated form thereof (sterol). Such novel **esters** exhibit the combined properties normally possessed by the sterol/sterol compd. and the **conjugated fatty acid** and as such are excellent additives for dietetic foods and supplements.

L13 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:136991 CAPLUS

DOCUMENT NUMBER: 134:198075

TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing

PATENT ASSIGNEE(S): Lipocine, Inc., USA

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012155	A1	20010222	WO 2000-US18807	20000710
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

1/7/2003

09553386

US 6309663 B1 20011030 US 1999-375636 19990817
EP 1210063 A1 20020605 EP 2000-947184 20000710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL
US 2001024658 A1 20010927 US 2000-751968 20001229
US 6458383 B2 20021001

PRIORITY APPLN. INFO.: US 1999-375636 A 19990817
WO 2000-US18807 W 20000710

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the compn., or can be co-administered with the compn. as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a compn. contg. Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:344854 CAPLUS

DOCUMENT NUMBER: 130:347399

TITLE: Use of mixtures containing phytostenols for producing hypocholesteremic preparations

INVENTOR(S): Fabry, Bernd

PATENT ASSIGNEE(S): Henkel Kommanditgesellschaft auf Aktien, Germany

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925362	A1	19990527	WO 1998-EP7059	19981105
W:	AU, BG, BR, BY, CA, CN, CZ, HU, ID, IS, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SI, SK, TR, UA, US			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
DE 19750453	A1	19990527	DE 1997-19750453	19971114
CA 2310026	AA	19990527	CA 1998-2310026	19981105
AU 9915603	A1	19990607	AU 1999-15603	19981105
AU 737638	B2	20010823		
EP 1028733	A1	20000823	EP 1998-959848	19981105
R:	DE, ES, FR, GB, IT, NL			
JP 2001523641	T2	20011127	JP 2000-520795	19981105

PRIORITY APPLN. INFO.: DE 1997-19750453 A 19971114
WO 1998-EP7059 W 19981105

OTHER SOURCE(S): MARPAT 130:347399

AB Mixts. of active agents contg. (a) phytostenols and/or phytostenol esters and (b) conjugated fatty acids or their glycerides are used to produce hypocholesteremic prepns. These mixts. have a synergistic effect in reducing the cholesterol content of serum. When encapsulated in gelatin, the prepns. can be administered

1/7/2003

orally in high doses without any problems; they may also be incorporated into food products. Thus, the contents of a 1.5-g capsule, contg. 5 wt.% .beta.-sitostanyl laurate, 5 wt.% **conjugated** linoleic acid, and radiolabeled **cholesterol**, were administered to fasting rats by gavage. The radioactivity level in the blood 48 h later was 12% of that in rats fed labeled **cholesterol** alone, and was also markedly lower than that in rats given either the phytostanol or the **fatty acid** alone.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:771359 CAPLUS

DOCUMENT NUMBER: 130:25230

TITLE: Use of selected phytosterol **esters** for preparation of hypocholesterolemic agents

INVENTOR(S): Fabry, Bernd

PATENT ASSIGNEE(S): Henkel K.-G.a.A., Germany

SOURCE: Ger., 6 pp.

CODEN: GWXXAW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19750422	C1	19981126	DE 1997-19750422	19971114
CA 2309325	AA	19990527	CA 1998-2309325	19981105
WO 9925361	A1	19990527	WO 1998-EP7057	19981105
W: AU, BG, BR, BY, CA, CN, CZ, HU, ID, IS, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, TR, UA, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9915602	A1	19990607	AU 1999-15602	19981105
AU 737048	B2	20010809		
EP 1028732	A1	20000823	EP 1998-959847	19981105
R: DE, ES, FR, GB, IT, NL				
JP 2001523640	T2	20011127	JP 2000-520794	19981105
PRIORITY APPLN. INFO.:			DE 1997-19750422 A	19971114
			WO 1998-EP7057 W	19981105

AB Use of phytosterol **esters** of unsatd. **conjugated** fatty acids for prepn. of hypocholesterolemic agents is described. Thus, in a gelatin capsule is added a mixt. of different .beta.-sitosterol **esters** (5%), radioactively-labeled **cholesterol** (0.5%) and if necessary vitamin E. The blood of animals receiving these capsules were tested for radioactivity at 3, 6, 12, 24, and 48 h; after 48 h radioactivity was down to 15-21%.

L13 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:406605 CAPLUS

DOCUMENT NUMBER: 123:179356

TITLE: Antibodies to atherosclerotic plaque-specific antigens and their uses

INVENTOR(S): Ditlow, Charles C.; Chen, Francis W.; Calenoff, Emanuel

PATENT ASSIGNEE(S): Scotgen Biopharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 288 pp.

CODEN: PIXXD2

09553386

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9425053	A1	19941110	WO 1994-US4641	19940426
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5955584	A	19990921	US 1993-53451	19930426
AU 9467758	A1	19941121	AU 1994-67758	19940426
EP 707489	A1	19960424	EP 1994-915914	19940426
R: DE, FR, GB, IT, NL				
PRIORITY APPLN. INFO.:			US 1993-53451	19930426
			US 1986-846401	19860331
			US 1986-871811	19860606
			US 1986-876741	19860620
			US 1987-67986	19870629
			US 1987-67993	19870629
			US 1987-67995	19870629
			US 1989-388129	19890731
			US 1992-828860	19920131
			WO 1994-US4641	19940426

AB A sterol such as 5,7-cholestadien-3.beta.-ol (7-dehydrocholesterol) or a compd. having a structure similar to 5,7-cholestadien-3.beta.-ol and a quaternary ammonium salt act as surrogate antigens for antibodies capable of binding to atherosclerotic plaque. Also provided is a method of generating an antibody using the surrogate antigens, as well as the antibodies produced thereby and fragments of such antibodies. The invention also provides a rat myeloma cell line Z2D3 73/30 1D10 and a murine-human chimeric monoclonal antibody produced by this cell line. A CDR-grafted antibody comprising a CDR region amino acid sequence from hybridoma Z2D3 or hybridoma Z2D3/3E5 and framework and const. region amino acid sequences from a human Ig in further provided. Also provided are methods for imaging atherosclerotic plaque, ablating atherosclerotic plaque, detecting and quant. detg. an antigen indicative of the presence of atherosclerotic plaque, reducing the amt. of atherosclerotic plaque in a blood vessel, and treating atherosclerosis in a subject. The invention also provides peptides having amino acid sequences which are the same or substantially the same as those of the aforementioned murine-human chimeric monoclonal antibody, as well as isolated nucleic acid sequences encoding these peptides.

L13 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1987:493262 CAPLUS

DOCUMENT NUMBER: 107:93262

TITLE: Growth support and metabolism of phytosterols in
Paramecium tetraurelia

AUTHOR(S): Whitaker, Bruce D.; Nelson, David L.

CORPORATE SOURCE: Coll. Agric. Life Sci., Univ. Wisconsin, Madison, WI,
53706, USA

SOURCE: Lipids (1987), 22(6), 386-96
CODEN: LPDSAP; ISSN: 0024-4201

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Under certain conditions, **sterols** that fail to support growth (e.g., **cholesterol**) can be esterified in large amts. of Paramecium. There was no compelling evidence to support the hypothesis

1/7/2003

that steryl **esters** serve a specialized role in the **fatty acid** metab. of the cell. Octadecenoic acid, essential for cell growth, was the major **fatty acid** in both steryl **esters** and triglycerides. *P. tetraurelia* Dehydrogenated .DELTA.0 and .DELTA.7, as well as .DELTA.5-3.beta.-hydroxy **sterols**, to yield the **conjugated** 5,7-diene deriv. These results indicate the presence of a .DELTA.5, in addn. to a .DELTA.7, desaturase of the sterol nucleus in this ciliate. Two C24 .alpha.-Et **sterols**, .DELTA.22-stigmastanol (.DELTA.22) and stigmastanol (.DELTA.0), were shown for the first time to promote growth. Finally, it was found that non-growth-promoting **sterols** may compose a high percentage of the free **sterols** of the surface membrane without adversely affecting cell growth or viability. These data support the conclusion that the growth requirement for select phytosterols in *Paramecium* does not involve the structural or functional role of bulk **sterols** in cell membranes.

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1986:587628 CAPLUS

DOCUMENT NUMBER: 105:187628

TITLE: Seeds of *Colliguaya intergerrima* Gillies - Hooker (Euphorbiaceae). Chemical composition of the crude extracted oil and the residual meal

AUTHOR(S): Bertoni, M. H.; Gomez, R. G.; Cattaneo, P.

CORPORATE SOURCE: Fac. Cienc. Exactas Nat., Univ. Buenos Aires, Buenos Aires, Argent.

SOURCE: Anales de la Asociacion Quimica Argentina (1986), 74(3), 229-35

CODEN: AAQAAE; ISSN: 0365-0375

DOCUMENT TYPE: Journal

LANGUAGE: Spanish

AB Seeds of *C. intergerrima*, a potential new source of drying fixed oils, yielded 54.9% crude oil (hexane extd., dry basis) whose main characteristics were iodine no. 151.3; unsaponifiable matter 1.18%; lipidic P 60 mg%g; total tocopherols 41 mg%g and total **sterols** 401 mg%g. The **fatty acid** compn. (% of total) was 16:0, 10.6; 18:0, 1.9; 18:1, 18.7; 18:2, 38.5; 18:3, 23.6; 20:1, 6.3; 20:2, 0.4; and traces of 14:0 and 17:0. Total **fatty acid** Me **esters** showed very low absorptivities in the UV for triene and tetraene **conjugated** double bonds (0.04 and 0.02% expressed as .beta.-eleostearic and .beta.-parinaric acids, resp.). **Cholesterol** (4.9), campesterol (2.1), stigmastanol (0.8), and sitosterol (92.2% of total **sterols** identified) were found. General compositional values for the residual seed meal (which is possibly toxic) and for the protein isolate are given.

L13 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1963:457431 CAPLUS

DOCUMENT NUMBER: 59:57431

ORIGINAL REFERENCE NO.: 59:10583f-h,10584a-b

TITLE: Lipid excretion. III. Examination of fecal lipids of rats injected intravenously with serum lipoprotein containing C14-labeled **cholesterol**

AUTHOR(S): Wood, P. D. S.; Aylward, F.; Pilkington, T. R. E.

CORPORATE SOURCE: Borough Polytechnic, London

SOURCE: Brit. J. Nutr. (1963), 17, 89-104

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB cf. CA 58, 4901c. Feces from 3 groups of rats were examd., 1 group

maintained on a diet with 2.5% fat (low-fat), the feces contained no C14; and 2 groups on diets with 25.0% fat (high-fat) contg. either soybean oil or butter, and the feces contained C14. The diet of the rats on oil or butter was changed to low-fat and 1 day later they were injected intravenously with serum lipoproteins derived from other rats on high-fat diets contg. C14-labeled free and ester **cholesterol**; the feces examd. were collected for the 2 days after injection. Chem. fractionation techniques used for human feces (CA 58, 4901d) were successful and indicated a pattern of lipid distribution in rat feces similar in many respects to human feces. Lipids present included free fatty acids, **sterols** and sterol **esters**, long chain waxes and alcs., phospholipids, hydrocarbons, and free and **conjugated** bile acids, and mono- and di-glycerides. Rat feces contained a much smaller proportion of **fatty acid** soaps, pigments, and triglycerides than typical human feces. Daily excretion of bile acids by rats on a high-fat diet was considerably greater than of those on a low-fat diet. Distribution of C14 in fecal lipid fractions from injected rats could be satisfactorily studied in spite of the low level of activity. Activity was negligible in free or combined fatty acids, phospholipids, long-chain waxes and alcs., but was present in all bile acid and sterol fractions. For rats given oil or butter the activity excreted as the bile acids:**sterols** ratio was >2:1. Activity was present in sterol **esters** and in unsaponifiable substances more polar than **cholesterol**, probably including steroid diols and triols. The sp. activity of these fractions suggested that in each substance active material derived from serum **cholesterol** had been considerably slight, with most substances of dietary or bacterial origin.

09553386

=> s l3 and fish oil

114748 FISH

639842 OIL

7295 FISH OIL

(FISH(W)OIL)

L17 2958 L3 AND FISH OIL

=> s l17 and conjugated

81735 CONJUGATED

L18 41 L17 AND CONJUGATED

=> s l18 and phytosterols

1449 PHYTOSTEROLS

L19 0 L18 AND PHYTOSTEROLS

=> s l18 and esters

356293 ESTERS

L20 9 L18 AND ESTERS

=> s l20 and phytosterols

1449 PHYTOSTEROLS

L21 0 L20 AND PHYTOSTEROLS

=> s l20 and cholesterol

135044 CHOLESTEROL

L22 2 L20 AND CHOLESTEROL

=> d l22 ibib hitstr abs

L22 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:431748 CAPLUS

DOCUMENT NUMBER: 135:18815

TITLE: Therapeutically effective antiatherosclerotic and
antiobesity composition, a procedure for its
production and use.

INVENTOR(S): Sagredos, Angelos

PATENT ASSIGNEE(S): Germany

SOURCE: Ger. Offen., 8 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19956400	A1	20010613	DE 1999-19956400	19991124
PRIORITY APPLN. INFO.:			DE 1999-19956400	19991124

AB The invention concerns a therapeutically effective compn. characterized by a combination of **conjugated** linoleic acids and/or their nontoxic salts and/or **esters** with .omega.-3-fatty acids and/or their non-toxic salts and/or **esters**, in particular .omega.-3-**fatty acid** triglycerides, and/or a **fish oil** enriched with .omega.-3-fatty acids. Furthermore the invention concerns a procedure for the prodn. of the compn. and its use for dietetic, oral and parenteral applications for the treatment of hypercholesteremia, coronary heart disease and fatty liver and other organ obesity states in humans and animals.

1/7/2003

09553386

REFERENCE COUNT:

1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>